Dr Errol De Souza is a leader in the development of therapeutics for treatment of central nervous system (CNS) disorders.
He is the president and chief executive of Neuropore Therapies Inc. Prior to that Dr De Souza was the president and chief executive of US biotech companies Biodel Inc, Archemix Corporation and Synaptic Pharmaceutical Corporation. He also held senior management positions at Aventis Pharmaceuticals (now Sanofi) and its predecessor Hoechst Marion Roussel Pharmaceuticals Inc, senior vice president and site head of US drug innovation and approval (R&D), at Aventis where he was responsible for the discovery and development of drug candidates through Phase IIa clinical trials for CNS and inflammatory disorders. Prior to Aventis, he was a co-founder and chief scientific officer of Neurocrine Biosciences.
Dr De Souza served on multiple editorial boards, National Institutes of Health Committees, and is a director of several public and private companies.
